Posts

When Surveillance Turns to Surgery: What a Norwegian Study of 7,600 Men Tells Us

Image
Surveillance Before Prostatectomy Tied to Adverse Pathology Men who had surgery after a period of active surveillance had more advanced disease in the removed prostate, but their ten-year survival was the same. The lesson is about how surveillance is done, not whether to do it. Stephen L. Pendergast, IPCSG  |  September 2026 Bottom Line Up Front A nationwide Norwegian registry study published September 19, 2026 in the World Journal of Urology compared 1,839 men who had their prostate removed after a period of active surveillance with 5,767 similar men who had surgery right away. The surveillance-then-surgery group had about twice the odds of "adverse pathology" (cancer that was higher grade or had grown beyond the prostate) and a roughly 50% higher adjusted chance of needing radiation or hormone therapy after surgery. 1 The reassuring part: ten-year prostate cancer survival did not differ between the two groups, and three out of four men on surveillance never we...
Post a Comment
Read more

What the July 2026 FDA Expansion Means for Men with Advanced Prostate Cancer

Image
Sharp Memorial offers new treatment for advanced prostate cancer – NBC 7 San Diego Pluvicto Moves Earlier:  A San Diego Navy veteran's story, the research behind the headlines, and the questions to bring to your next oncology visit. By Stephen L. Pendergast, IPCSG  |  September 2026 (Prostate Cancer Awareness Month) Bottom Line Up Front On July 31, 2026, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), given together with a modern hormone pill (an ARPI), for men whose PSMA-positive prostate cancer has spread but still responds to hormone therapy . Until now, Pluvicto was limited to men whose cancer had stopped responding to hormones. Novartis says the change nearly doubles the number of eligible men. The approval rests on the PSMAddition trial of 1,144 men. Adding Pluvicto to standard hormone therapy lowered the risk of cancer progression or death by 28% at the primary analysis and by 33% at an updated analysis. A survival advantage is trending in ...
Post a Comment
Read more

Momentum in Advanced Prostate Cancer: What the Last Month Delivered for Men Living with Metastatic Disease

Image
Special Report:  Informed Prostate Cancer Support Group  •  San Diego, California IPCSG Member Newsletter  •  Research & Treatment Update September 2026  •  Educational Use Only For men living with metastatic castration-resistant prostate cancer (mCRPC) and their families, the weeks from mid-August through mid-September 2026 brought a steady drumbeat of encouraging news. Radioligand therapy continued its march across every stage of metastatic disease, a new generation of immune-based "T-cell engagers" moved deeper into late-stage testing, precision medicine pressed earlier into the disease course, and a landmark government action promised real relief on the price of one of our most-used pills. This report gathers those developments in one place, with an eye toward what they mean for men whose disease no longer responds to hormone therapy alone. 1. Radioligand therapy: now a tool for every stage The biggest story of t...
Post a Comment
Read more

Deleting the Target: Eliminating Androgen Receptors

Image
  Clinical Trials & Emerging Therapies A New “AR-Degrader” Trial Opens for Advanced Prostate Cancer GSK has begun the first human study of GSK5471713, an experimental drug designed not just to block the androgen receptor but to destroy it. Here is what the trial does, why it asks for the patients it asks for, and how a man might think through whether joining makes sense. for the IPCSG Newsletter  |  Reviewed September 2026 Bottom Line Up Front A new Phase 1/2 clinical trial (identifier NCT07332455 ) is now recruiting men with metastatic castration-resistant prostate cancer (mCRPC) to test GSK5471713 , an experimental GSK drug that belongs to the emerging class of androgen-receptor (AR) degraders . Instead of merely blocking the receptor the way enzalutamide or abiraterone do, degraders aim to tag the AR protein for the cell’s own disposal system so it is broken down entirely. This is an early, first-in-human study . Its main job is to find...
Post a Comment
Read more

A New Kind of Immune Therapy Comes to San Diego:

Image
IPCSG Newsletter · Research on the Horizon The JANX014 Trial A "double-masked" T-cell engager for advanced prostate cancer has entered its first human study — developed by a San Diego company and being tested close to home. Prepared for the Informed Prostate Cancer Support Group · September 2026 Bottom Line Up Front JANX014 is an experimental prostate-cancer immunotherapy now in its earliest stage of human testing (Phase 1) for men with metastatic castration-resistant prostate cancer (mCRPC) . It is a "double-masked" T-cell engager — a drug engineered to stay switched off in the bloodstream and turn on only after it reaches the tumor, an approach meant to widen the safety margin and reduce the immune-overactivation reaction (cytokine release syndrome) that has limited earlier drugs of this type. It is made by San Diego–based Janux Therapeutics , and the study is recruiting at six U.S. centers — the first of which is UC San Diego's Moore...
Post a Comment
Read more